Abstracts tagged "cardiovascular disease and tofacitinib"

Abstract Number: 2966 • 2017 ACR/ARHP Annual Meeting
Impact of Tofacitinib Treatment Compared with Placebo or Methotrexate on Cardiovascular Risk Scores in Six Phase 3 Randomized Controlled Trials
Michael Nurmohamed¹, Ernest Choy², Christina Charles-Schoeman³, George Kitas⁴, Paola Accossato⁵, Piotr Szczypa⁶, Konstantina Chouchouli⁷, Tatjana Lukic⁸ and Pinaki Biswas⁸, ¹VU University Medical Centre, Amsterdam, Netherlands, ²CREATE Center, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom, ³University of California, Los Angeles, Los Angeles, CA, ⁴Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ⁵Pfizer S.r.l, Rome, Italy, ⁶Pfizer Ltd, Walton Oaks, United Kingdom, ⁷Pfizer Hellas S.A, Neo Psychiko, Greece, ⁸Pfizer Inc, New York, NY
Background/Purpose: Patients (pts) with RA are at increased risk of myocardial infarction and stroke not fully explained by usual cardiovascular (CV) risk factors. Tofacitinib is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].